<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Unit I ‚Äì Human Anatomy & Physiology I (BP101T)</title>
<meta name="viewport" content="width=device-width, initial-scale=1.0">

<style>
body{
  margin:0;
  padding:30px 20px;
  background:#f6f0e4;
  font-family:Arial, Helvetica, sans-serif;
  color:#000;
  text-align:center;
}

/* Back link */
.back{
  color:#0000ee;
  text-decoration:none;
  font-size:14px;
  display:inline-block;
  margin-bottom:15px;
}

/* Headings */
h1{
  color:#c4002f;
  margin:10px 0 5px;
}
h2{
  font-size:18px;
  font-weight:normal;
  margin-bottom:25px;
}

/* Notes container */
.notes{
  max-width:900px;
  margin:0 auto;
  background:#ffffff;
  padding:30px;
  border-radius:6px;
  border:2px solid #c4002f;
  text-align:left;
}

/* Section titles */
.notes h3{
  color:#c4002f;
  margin-top:25px;
}

/* Paragraphs */
.notes p{
  line-height:1.7;
  margin:10px 0;
}

/* Lists */
.notes ul{
  margin:10px 0 10px 20px;
}
.notes li{
  margin:6px 0;
}

/* Button */
.action-btn{
  background:#ffffff;
  border:2px solid #c4002f;
  color:#c4002f;
  padding:12px 22px;
  font-size:14px;
  font-weight:600;
  text-decoration:none;
  border-radius:6px;
  display:inline-block;
  cursor:pointer;
  transition:all 0.2s ease;
}

.action-btn:hover{
  background:#c4002f;
  color:#ffffff;
}
</style>
</head>

<body>
<a href="../index.html" class="back">‚Üê Back to BP101T</a>
<header>
<h1>UNIT I</h1>
<h2>Introduction to Human Anatomy & Physiology</h2>
<p><strong>Subject:</strong> Human Anatomy and Physiology-I (BP101T)</p>
<p><strong>Prepared by:</strong> Mr. Rahul Singh Shaktawat</p>
</header>
<!-- DOWNLOAD / VIEW BUTTON -->
<div class="btn-area">
  <a
    href="https://drive.google.com/file/d/1qqCe5psYOMHwkO0zuaGIAs6kLDG9BRRr/view?usp=sharing"
    class="action-btn"
    target="_blank"
    rel="noopener noreferrer"
  >
    üìÑ View / Download Unit I Notes (PDF)
  </a>
</div>
<!-- NOTES CONTENT -->
<div class="notes">
<div class="container">
<body>
  <section id="ira5">
<body id="iw51">
  <h1 id="iia3">new
  </h1>
  <section id="i646">
    <h2>Extracted PDF Content
    </h2>
    <p>Garg   et al .   European Journal of Pharmaceutical and Medical Research  www.ejpmr.com   207  GENE THERAPY   ‚Äì   A REVIEW  1* Ayush Garg,   2 Salil Sanghvi,   3 Krunal Trivedi and   4 Hitesh Chaturvedi  1,2,3,4 Dept. of Pharmaceutics, Pacific College of Pharmacy, Udaipur   ‚Äì   313024.  Article Received on 05/01/2018   Article Revised on 08/01/2018   Article Accepted on 18/02/2018  INTRODUCTION  In gene therapy, a functional or healthy or useful gene is introduced into the cell or a tissue to cure heritable disorders and the defective or faulty gene is replaced by the new useful gene (Figure 1).  Figure 1: A flowchart representing gene therapy. There are two kinds of gene therapy  1.   Germ line gene therapy. 2.   Somatic cell gene therapy.  Germ line gene therapy   is a kind of gene therapy in which DNA is transferred to cells that produce eggs or sperm. The main advantages of germ-line cell gene therapy are the following. 1.   It offers the possibility for a true cure of several diseases and it is not only a temporary   solution. 2.   It might be the only way to treat some genetic diseases. 3.   The   benefits   would   be   extended   for   several generations, because genetic defects are eliminated  in the individual‚Äôs genome and, consequently, the  benefits would be passed to his or her offspring. Some of the objections of germ-line cell gene therapy are as follows. 1.   This involves many steps that are poorly understood, and the long-term results cannot be estimated. 2.   It would open the door for genetic modifications in human   traits   with   profound   social   and   ethical implications. 3.   It is very expensive and it would not benefit the common citizen. 4.   The extension of the cure to a person‚Äôs offspring  would be possible only if the defective gene was directly modified, but probably not if a new gene was added to another part of the genome. [1]  Somatic cell gene therapy   is a kind of gene therapy in which   the   therapeutic   genes   are   transferred   into   the somatic cells of a patient (DNA transfer to our normal body tissue). The results of any somatic gene therapy are restricted to the actual patient and are not passed on to his or her children.  VECTORS FOR GENE THERAPY  There are basically three vectors for gene therapy.  SJIF Impact Factor 4.897  Review   Article  ISSN 2394 - 3211  EJPMR  EUR OPEAN JOURNAL OF PHARMACEUTICAL  AND MEDICAL RESEARCH  www.ejpmr.com  ejpmr, 2018,5(3),   207 - 209  Corresponding Author: Ayush Garg  Dept. of Pharmaceutics, Pacific College of Pharmacy, Udaipur   ‚Äì   313024.  ABSTRACT  The ability to transfect genes into cells and to cause their expression is leading to the practical emergence of human gene therapy, wherein, functionally active genes are putatively inserted into the (somatic) cells of a person requiring the expression of a given protein. A novel adaptation of gene therapy is the transfection of cells with non- resident genes in order to accomplish in situ expression of a pharmacologically beneficial protein or create a site for further therapeutic intervention. In other words, genes would act like drugs, generating a product with a specific pharmacological effect. In simple term s, gene therapy involves insertion of genetic material into a patient‚Äôs cells to  make them capable of producing therapeutic protein.  KEYWORDS:   Gene, germ line, somatic, retrovirus, vectors.
      <br/>
      <br/>Garg   et al .   European Journal of Pharmaceutical and Medical Research  www.ejpmr.com   208  1.   Virus (Figure 2) 2.   Non-virus method 3.   Hybrid method (combination of virus + non-virus method)  Virus  Viruses used for gene therapy are. a.   Retro-virus. b.   Adenovirus. c.   Adeno-associated virus (non-pathogenic). d.   Enveloped protein pseudo typing of virus vector. [2, 3]  Figure 2: Viral method of gene therapy  a.   Retro-virus  In retrovirus the genetic material is in the form of RNA molecules, while that in the host is in the form of DNA. A class of viruses that can create double-stranded DNA copies   of   their   RNA   genomes.   These   copies   of   its genome can be integrated into the chromosomes of host cells.   Human   immunodeficiency   virus   (HIV)   is   a retrovirus.  b.   Adenovirus  A class of viruses with double-stranded DNA genomes that cause respiratory, intestinal, and eye infections in humans. The virus that causes the common cold is an adenovirus.  c.   Adeno-associated Virus  It is a class of small, single-stranded DNA viruses that can insert their genetic material at a specific site on chromosome 19. [4]  d.   Enveloped Protein Pseudo typing of Virus Vector  A classical example of such a vector is VSV-G pseudo typed lenti-virus (G-protein and Vesicular Somatis Virus coat added to lenti-virus).  e.   Herpes simplex viruses  These are a class of double-stranded DNA viruses that infect a particular cell type, neurons. Herpes simplex virus type 1 is a common human pathogen that causes cold sores. [5]  Non- Virus Method  These include. 1.   Naked DNA injected intra-muscularly, by gene gun, sonoporation and electroporation 2.   Oligonucleotides:   Synthetic   oligonucleotides inactivate genes involved in a disease process 3.   Lipoplexes and polyplexes:   DNA is coated   with lipids and is called liposome (Figure 3). Polyplexes are complex polymers with DNA and consist of cationic polymers. [6]  Figure 3: Liposome for drug delivery. Hybrid Method  These include 1.   Virosomes ( Virus + Liposomes)  2.   Dendrimers   (Macromolecules   with   cationic structure) [7]  DISEASES AND GENE THERAPY  Diseases wherein gene therapy has been focused upon include 1.   Cystic fibrosis. 2.   Thalassaemia. 3.   Malignant melanoma. 4.   Pediatric AML. 5.   Neuroblastoma. 6.   Adenosine deaminase deficiency SCID. 7.   Hemophilia B. 8.   Chronic myleogenous leukemia. 9.   Hepatitis B. 10.   Hypercholesterolemia. 11.   Diabetes. 12.   Cardiovascular diseases. 13.   Phenylketonuria. 14.   Acquired immunodeficiency syndrome (AIDS). [8]  PROBLEMS OF GENE THERAPY  1.   The short-lived nature of gene therapy: Before gene therapy   can   become   a   permanent   cure   for   any condition, the therapeutic DNA introduced into the target cells must remain functional and the cells containing therapeutic DNA must be long-lived and stable.
      <br/>
      <br/>Garg   et al .   European Journal of Pharmaceutical and Medical Research  www.ejpmr.com   209  2.   Immune   system   produces   a   response   against invaders and it is difficult for gene therapy to be repeated. 3.   Virus vector used in gene therapy presents many problems. 4.   Multi-genic   disorders   (Gene   therapy   is   used   for disorders that arise from mutation of single gene. But diseases such as heart failure, blood pressure,  arthritis, diabetes, Alzheimer‚Äôs disease,   etc.,   which are due to multiple genes, cannot be treated. 5.   Chances of inducing tumor (if DNA is interplaced at wrong place). [9, 10]  SUMMARY AND CONCLUSION  Gene therapy‚Äôs potential to revolutionize medicine in the  future is exciting, and their expectation for curing and preventing childhood diseases is encouraging. One day it may be possible to treat an unborn child for a genetic disease   even   before   symptoms   appear.   Scientists   are hoping the mapping of the human genome will lead the way   toward   cures   for   many   diseases   and   that   the successes   of   current   clinical   trials   will   create   new opportunities and challenges. With the explosive increase in the availability of information on human genome, several genetic disorders would become candidates for gene therapy. The field is still at its infancy and relevant. Inspite   of   the   various   drawbacks,   gene   therapy   has witnessed a rapid growth towards the end of this century and hopefully the progress would continue.  REFERENCES  1.   Akhtar,   S.,   James,   H.   and   Gibson,   I.   Nature Medicine, 1995; 1: 300-302. 2.   Cohen, J.S. Pharmacol. Ther, 1991; 52: 211-225. 3.   Crstal, R.G. Nature Genet, 1994; 8: 42-51. 4.   Patil P.M., Chaudhari P.D., Megha Sahu, Duragkar N.J. Review Article on Gene Therapy. International Journal of Genetics, 2012; 4(1): 74-79. 5.   Inouye, M. Gene, 1988; 72: 25-34. 6.   Gao, X.A. and Huang, L. Biochim. Biophys. Res. Commun, 1991; 179: 280-285. 7.   Strauss,   J.H.   and   Strauss,   E.G.   Microbiol.   Rev, 1994; 58: 491-562. 8.   Palmer, T.D., Thompson,   A.R. and Miller,   A.D. Blood, 1989; 73: 438-445. 9.   Zhao, X., Zhange, P.J. and Wong, T.K. Mol. Marine Biol. Biotech, 1993; 2: 63-69. 10.   Ramawat, K.G. and Tanwar, Y.S., Pharmaceutical Biotechnology, Yash Publishing House, Bikaner, 1 st  Edn, 2007; 196-206.
      <br/>
      <br/>
    </p>
  </section>
</body>
      <br/>
    </p>
  </section>
</body>
</body>
</html>
